<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Modern Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Modern Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Современная онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1815-1434</issn><issn publication-format="electronic">1815-1442</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64964</article-id><article-id pub-id-type="doi">10.26442/18151434.2021.3.200907</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL ONCOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Can any breast skin thickening be staged as T4?</article-title><trans-title-group xml:lang="ru"><trans-title>Можно ли стадировать любое утолщение кожи молочной железы как T4?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7207-631X</contrib-id><contrib-id contrib-id-type="spin">4726-5951</contrib-id><name-alternatives><name xml:lang="en"><surname>Amosova</surname><given-names>Viktoriia A.</given-names></name><name xml:lang="ru"><surname>Амосова</surname><given-names>Виктория Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>oncologist</p></bio><bio xml:lang="ru"><p>врач-онколог, отд. телемедицины</p></bio><email>amosova_va@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7514-280X</contrib-id><contrib-id contrib-id-type="scopus">36949543000</contrib-id><contrib-id contrib-id-type="spin">5441-2747</contrib-id><name-alternatives><name xml:lang="en"><surname>Petrovskii</surname><given-names>Aleksandr V.</given-names></name><name xml:lang="ru"><surname>Петровский</surname><given-names>Александр Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, зам. дир. по образовательной деятельности, зав. хирургическим отд-нием №15 (комбинированного лечения опухолей молочной железы), доц. каф. онкологии</p></bio><email>amosova_va@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4945-982X</contrib-id><name-alternatives><name xml:lang="en"><surname>Karpova</surname><given-names>Marina S.</given-names></name><name xml:lang="ru"><surname>Карпова</surname><given-names>Марина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирантка рентгенодиагностического отд-ния лучевой диагностики и рентгенохирургических методов лечения</p></bio><email>amosova_va@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8047-3523</contrib-id><name-alternatives><name xml:lang="en"><surname>Ponedel’nikova</surname><given-names>Nataliia V.</given-names></name><name xml:lang="ru"><surname>Понедельникова</surname><given-names>Наталия Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>amosova_va@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8149-0085</contrib-id><contrib-id contrib-id-type="spin">2809-7737</contrib-id><name-alternatives><name xml:lang="en"><surname>Frolova</surname><given-names>Mona A.</given-names></name><name xml:lang="ru"><surname>Фролова</surname><given-names>Мона Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. химиотерапевтического отд-ния №2</p></bio><email>amosova_va@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Blokhin National Medical Research Center of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-11-19" publication-format="electronic"><day>19</day><month>11</month><year>2021</year></pub-date><volume>23</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>466</fpage><lpage>469</lpage><history><date date-type="received" iso-8601-date="2021-04-08"><day>08</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://modernonco.orscience.ru/1815-1434/article/view/64964">https://modernonco.orscience.ru/1815-1434/article/view/64964</self-uri><abstract xml:lang="en"><p>Data analysis showed that many diagnostic issues in breast cancer patients with skin involvement are not systematized. In some cases when the tumor is small and skin involvement symptoms are minimal ("local" skin edema), should this category of patients be considered as patients with non-inflammatory skin involvement breast cancer? Current research confirms the presence of skin involvement has much less prognostic value than, for example, tumor size or lymph node metastases, and the surgical term "unresectable" may not always be adequate. In addition, clinical data often do not correspond to pathological data, which also complicates the staging and leads to "overtreatment" of such patients. Thus, further research is needed to identify categories of breast cancer (patients with skin involvement similar in prognosis, as well as to individualize approaches to local and systemic treatment.</p></abstract><trans-abstract xml:lang="ru"><p>Анализ данных научной литературы показал, что многие вопросы, касающиеся диагностики рака молочной железы с вовлечением кожи в опухолевый процесс, не систематизированы. Так как в некоторых случаях опухолевый узел имеет небольшие размеры, а симптомы вовлечения кожи могут быть менее выражены («локальное» проявление отека кожи), стоит ли рассматривать такую категорию пациентов как пациентов с вторичной отечно-инфильтративной формой? Изучение актуальных исследований свидетельствует о том, что наличие отека кожи в целом имеет гораздо меньшее прогностическое значение, чем, например, размер опухоли или уровень поражения регионарных лимфоузлов, а использование хирургического термина «неоперабельный процесс» далеко не всегда является адекватным. Кроме того, клинические данные зачастую не соответствуют патоморфологическим, что также затрудняет вопрос стадирования и, как следствие, ведет к «перелечиванию» таких пациентов. В этой ситуации необходимы дальнейшие исследования, которые позволят определять категории пациентов, сходных по прогнозу, а также индивидуализировать подходы к локальному и системному лечению.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>patient staging</kwd><kwd>skin involvement</kwd><kwd>local edema</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>стадирование пациентов</kwd><kwd>поражение кожи</kwd><kwd>локальный отек</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>NCCN Guidelines Version 2.2021 Breast Cancer.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res. 2005;11:7637-42.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Edge SB, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York: Springer, 2010.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296-316.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Harms K, Wittekind C. Prognosis of women with pT4b breast cancer: the significance of this category in the TNM system. Eur J Surg Oncol. 2009;35(1):38-42.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wiggett WS, Louw M, Karusseit VO. The histology of peau d’orange in breast cancer – what are the implications for surgery? S Afr J Surg. 2012;50(3):75-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Güth U, Singer G, Schötzau A, et al. Scope and significance of non-uniform classification practices in breast cancer with non-inflammatory skin involvement: a clinicopathologic study and an international survey. Ann Oncol. 2005;16(10):1618-23.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Silverman D, Ruth K, Sigurdson ER, et al. Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg. 2014;219(3):534-44.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zucali R, Kenda R. Small Size-T4 Breast-Cancer. Natural History and Prognosis. Tumori. 1981;67(3):225-30.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Güth U, Wight E, Schötzau A, et al. A new approach in breast cancer with non-inflammatory skin involvement. Acta Oncol. 2006;45(5):576-83.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mateo AM, Mazor AM, DeMora L, et al. Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes. Clin Breast Cancer. 2019;19(4):292-303.</mixed-citation></ref></ref-list></back></article>
